A Phase 2 Study of TRS005 in Patients With CD20-positive R/R DLBCL.

Clinical trial NCT06886139 · NOT_YET_RECRUITING

Trial details

NCT number: NCT06886139
Sponsor: Zhejiang Teruisi Pharmaceutical Inc.
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

CD20-positive Diffuse Large B-Cell Lymphoma

Start date: 2025-09-01
Primary completion: 2027-01-01
Enrollment: 139

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.